Relay Therapeutics price target lowered to $46 from $47 at H.C. Wainwright » 06:1808/0908/09/22
H.C. Wainwright analyst…
H.C. Wainwright analyst Robert Burns lowered the firm's price target on Relay Therapeutics to $46 from $47 and keeps a Buy rating on the shares post the Q2 results.
|Over a week ago|
Relay Therapeutics reports Q2 EPS (71c) vs. ($2.10) last year » 17:0508/0408/04/22
As of June 30, cash,…
As of June 30, cash, cash equivalents and investments totaled approximately $838 million compared to $958 million as of December 31, 2021. Relay Therapeutics expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into at least 2025.
|Over a month ago|
Relay Therapeutics to hold virtual event » 07:4506/2706/27/22
Relay Therapeutics to hold virtual event » 04:5506/2706/27/22
Relay Therapeutics to hold virtual event » 16:5806/2506/25/22
Relay Therapeutics initiated with an Underperform at Jefferies » 08:0506/0606/06/22
Jefferies analyst Akash…
Jefferies analyst Akash Tewari initiated coverage of Relay Therapeutics with an Underperform rating and $13 price target. While the precision medicine company that goes after known oncology or genetic targets has an "interesting" approach, the stock is down about 48% year-to-date and at current levels Tewari still see risks given uncertainties around its three lead assets, RLY-2608, RLY-4008, and RLY-1971 given they are all still early-stage. Tewari also cites a lack of significant near-term catalysts with all three lead assets in Phase 1 development.
|Over a quarter ago|
Relay Therapeutics price target lowered to $47 from $54 at H.C. Wainwright » 06:1105/1005/10/22
H.C. Wainwright analyst…
H.C. Wainwright analyst Robert Burns lowered the firm's price target on Relay Therapeutics to $47 from $54 and keeps a Buy rating on the shares post the Q1 results. The company's "lengthy" cash runway positions it favorably compared to many peers in the biotech sector, which may need to raise capital either later this year or during 2023, Burns tells investors in a research note.
Relay Therapeutics price target lowered to $35 from $50 at JMP Securities » 06:4005/0905/09/22
JMP Securities analyst…
JMP Securities analyst Silvan Tuerkcan lowered the firm's price target on Relay Therapeutics to $35 from $50 and keeps an Outperform rating on the shares. Following early RLY-4008 data, pointing to a competitive profile, Tuerkcan believes a more mature update in 2022 from dose-escalation patients will drive interest, the analyst tells investors in a research note. Relay is also broadening the organization and plans to advance three additional oncology preclinical programs and two genetic disease preclinical programs, the analyst says.
Relay Therapeutics reports Q1 EPS (57c), consensus (62c) » 16:5205/0505/05/22
Reports Q1 revenue…
Reports Q1 revenue $419,000, consensus $170,000. "We have continued our execution focus into 2022, as we advance our portfolio of precision medicines towards patients," said Sanjiv Patel, Relay Therapeutics' president and chief executive officer. "With three programs in the clinic, we believe our platform and approach have the potential to address some of the hardest-to-treat diseases. We look forward to disclosing another innovative target next month as we continue on our journey of bringing life-changing therapies to patients."
Relay Therapeutics reports Q4 EPS ($3.82), consensus (58c) » 16:4102/2402/24/22
Reports Q4 revenue…
Reports Q4 revenue $3.03M, consensus $3.84M. "2021 was the year that Relay Therapeutics showed clinical data for the first time, with the RLY-4008 disclosure supporting our belief that our approach of integrating experimental techniques and computational power can make the discovery of medicines more efficient and effective," said Sanjiv Patel, president and chief executive officer. "We also grew our team, continued to execute against our deep and broad precision medicine pipeline and pushed the boundaries of our Dynamo platform, through both internal innovation and the integration of an acquisition. We've entered 2022 with three clinical stage programs, a robust preclinical pipeline and a cash runway into at least 2025. We are excited to continue our efforts to achieve our goal of bringing life-changing therapies to patients."